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Abstract
Despite the array of medical advances of our modern day society, infectious dis-
eases still plague millions of people worldwide. Malaria, in particular, causes sub-
stantial suffering and death throughout both developed and developing countries.
Aside from the socioeconomic challenges presented by the disease’s prevalence in im-
poverished nations, one of the major difficulties scientists have encountered while
attempting to eradicate the disease is the parasite’s ability to become resistant to
new drugs and methods of treatment. In an effort to better understand the dynamics
of malaria, we analyze a mathematical model that accounts for both the treatment
aspect as well as the drug resistance that accompanies it. Simulations demonstrating
the effects of treatment rates and the level of resistance are studied and discussed in
hopes of shedding additional light on the characteristics of this devastating epidemic.
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Chapter 1
Introduction
1.1 History
The word epidemic comes from the Greek epi and demos and means upon people. Epi-
demic diseases have often changed the course of history. Even early history records
use the term. The Bible tells us that lepers were cast away from society to be quar-
antined and to avoid transmission to the rest of the population. Some periods of
history revolve entirely around the epidemics that occurred like the Bubonic Plague,
Smallpox, Typhoid Fever and Influenza to name a few. The possibility of an out-
break these days would cause many people to shudder at the mention of such terrible
aﬄictions. For instance, Polio was one of the most dreaded maladies in the 1950s
that left many children crippled. The pain and agony that this disease caused was
well known to many people. We tend not to think of modern diseases as plagues that
could ransack an entire population, yet there are some diseases that are considered
to be at epidemic levels even in our modern society. One such infection is malaria.
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While instances of malaria were mentioned in some of the earliest texts, it con-
tinues to be problematic for many parts of the world, particularly those with tropical
environments. Malaria comes from the Italian term mal’ aria meaning bad air, due to
the common belief that malaria was an air-borne disease associated with swamps and
marshes. Ague was another term that was used in the 14th century to describe the
symptoms that accompany a malarial infection, coming specifically from the acute
intervals of chills, fever, and sweating induced by the parasite’s rapid multiplication
within the human host. The French refer to malaria as paludisme which originated
from paludis, Latin for swamp. Whatever the name, it remains that malaria is an
epidemic that should be eliminated.
1.2 The Extensive Reach of Malaria
Although our modern society recognizes the importance of disease control, oftentimes
malaria is overlooked due to its transparency within the media. Since malaria occurs
within rural areas, most public figures do not experience malaria, and so it is difficult
to raise awareness even though it aﬄicts many people.
“The figures are staggering, though perhaps constant repetition is pre-
venting some of us from fully grasping the implications: although over the
centuries malaria has been eradicated from many parts of the world simply
by draining swamps and marshes, and more deliberate malaria eradication
programs have further enabled many hundreds of millions to free them-
selves from the disease, there are still approximately 350 million people
in the world living in areas where the infection is endemic and where no
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organized antimalarial measures have yet been undertaken. The human
suffering caused by the disease alone is catastrophic enough, but when it
is remembered that the effects are often compounded by chronic under-
nutrition, economic underdevelopment, growing environmental stress and
pollution, together with social and political conflicts, the result virtually
amounts to an almost unrelieved state of disaster [2].”
The World Health Organization (WHO) estimates that approximately 50% of the
world is at risk for malaria. The people most at risk are children under five years
of age in the poorest countries in the world. There are reportedly near a billion
cases of malaria [10] every year with over 1 million of those cases resulting in death
[16]. It is estimated that Sub-Saharan Africa accounts over 90% of malaria fatalities
[3], with the majority of cases being undocumented due to their occurrence in rural
areas. Due to the lack of transportation and the rural location, many people suffer
without treatment. Many of these people are too poor to afford access to hospitals
and pharmacies even if they were within walking distance. These percentages should
be motivation enough for a global fight to end malaria as it continues to be one of
the most devastating diseases aﬄicting mankind. “Malaria is ranked among the most
frequent causes of morbidity and mortality among children and is often the leading
identifiable cause [3].”
Affected areas are illustrated by the shaded region shown in Figure 1.1. This map
shows that malaria occurs most often in tropical environments where conditions for
mosquito populations are ideal.
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Figure 1.1: Regions affected by malaria: The dark gray shows regions of the world
that are affected by malaria, with sub-Saharan Africa experiencing the largest portion
of this burden [3].
4
Chapter 2
Malaria
2.1 Symptoms
Malaria infection is accompanied by a suite of symptoms including waves of fever
and coldness, vomiting, anemia, and convulsions. Because it can be accompanied by
various symptoms that may resemble the common cold or other illnesses, malaria is
often misdiagnosed leading to incorrect treatment. Treatment options are generally
dictated by the region in which the infection occurs. Oftentimes treatment options
are not available due to the rural location and the lack of resources. Other times
drugs are administered incorrectly due to lack of education or misdiagnoses.
Chloroquine, the main drug used to combat malaria is inexpensive and was, at one
time, effective. Recent observations confirm that certain strains of the parasite that
causes malaria are becoming resistant to many drugs that have been widely used in the
past. This evolving resistance poses new obstacles when trying to control the spread
of malaria. Research is being conducted to explore the options that are available
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including combination therapy, mosquito (or vector) control, and vaccines. Some
of the most promising successes have been achieved using combination therapies in
which several different drugs are administered. The downfall of combination therapy
is that the cost is often too great for infected individuals to afford.
2.2 Causes and Pathogenesis
Malaria is caused by protozoan parasites of the genus Plasmodium. Within this
genus, five of over one hundred existing species are found to infect humans: P. falci-
parum, P. malariae, P. ovale, P. vivax, and P. knowlesi. The most common variant
in Africa is Plasmodium falciparum, which accounts for more than 50% of malaria
attacks [14] and most of the malaria fatalities. Malaria is transmitted to humans
by female Anopheles mosquitoes which obtain infection by biting an infected person.
The mosquito then carries the parasites within their salivary glands and transmits
them to a susceptible individual through a successive bite when the sporozoites are
injected from the mosquito’s salivary glands. The sporozoites then travel through the
human’s bloodstream and enter the liver and begin to multiply into merozoites for
several days.
Latent parasites of some species can dwell in the liver for a period of days or even
years, sometimes causing chronic cases of malaria. During these periods of latency, the
human is infected but would not be able to transmit the disease to other mosquitoes.
The individual does not experience the symptoms associated with infection at this
time. After multiplying, the merozoites migrate into red blood cells where they
continue to multiply, rupture red blood cells, and contaminate new red blood cells.
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Due to the fact that malaria stays within both the liver and the red blood cells, it is
difficult for the human immune system to detect and overcome the parasite.
2.3 Preventative Measures
Preventative measures such as mosquito control have proven to be very successful.
Many countries have banded together via the WHO to provide insecticide-treated nets
(ITNs) to impoverished areas that cannot afford them. These nets are effective, but
due to the level of poverty within these areas, the nets often become a trade resource
or a source of income for the people that receive them, since the nets can be sold
or used as fishing nets. Another preventative measure includes spraying pesticides
within the home, referred to as Indoor Residual Spraying (IRS), but mosquitoes
can then develop resistance to the pesticides as well. Some research has focused on
genetically engineering mosquitoes that are resistant to malaria infection. Although
much attention has been given to the research that focuses on developing a vaccine,
no vaccine exists to date.
2.4 Treatment
With documented cases of malaria as early as the fifth century BC [2], it is clear that
this parasite has endured many changes despite civilizations’ best efforts to eradicate
the epidemic. Some successful measures used in early times to counteract the spread
of malaria are still being exploited today. One commonly prescribed drug used to
treat malarial infections is Quinine which was isolated from the tree Cinchona. The
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Peruvian Indians started this practice by chewing the bark from the Cinchona tree
[2].
Another method to attempt to prevent malaria involves draining nearby swamps
and marshes, thereby reducing mosquito populations. It is unclear whether people
realized initially that by draining the marshes they were effectively reducing the
mosquitoes’ breeding grounds and thereby controlling the mosquitoes that carry the
disease.
Eventually the importance of mosquito control was realized in the 1930s and
1940s with the introduction of Dichloro-Diphenyl-Trichloroethane (DDT), a powerful
synthetic insecticide. At first, this pesticide proved to be a useful deterrent for the
mosquitoes, but over time the mosquito population began to develop resistance to
DDT. In the 1950s, the eradication of malaria was the focus of WHO as they continued
their efforts to prevent and treat the disease with a global campaign. These efforts
were successful at the time and many countries were able to effectively eradicate the
disease. Unfortunately, malaria continues to have a devastating presence in Africa
where drug resistance and insecticide resistance makes controlling outbreaks more
difficult. Another challenge is that many of the drugs that are available in Africa are
used incorrectly due to misdiagnoses. Even when used correctly, it is believed that
one of the main drugs, Chloroquine, has lost much of its effectiveness as a result of
overuse in some areas [3].
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2.5 Drug Resistance
Drug resistance is defined to be the ability of disease-causing organisms to adapt in
order to survive exposure to a drug that was at one time able to effectively kill the
organisms. Drug resistance occurs due to a random genetic mutation that allows
the organism to survive treatment. During replication, an organism sometimes ex-
periences a random mutation. If this mutation somehow combats the effectiveness
of treatment, these mutated organisms will continue to replicate and survive as their
non-mutated cousins will die during treatment [7]. The new drug resistant organisms
will continue growing regardless of human intervention.
Improper use of drugs aggravates the rise in drug resistance. For instance, if a fam-
ily has two children diagnosed with malaria, they may try to split the recommended
treatment between their two children if they cannot afford to buy more than one
treatment regimen. Taking smaller than recommended doses allows the pathogens to
be exposed to treatment without most of the organisms dying. A large number of the
organisms survive treatment increasing the likelihood that the surviving pathogens
have developed resistance to the drug. In fact, misuse of drugs is arguably the leading
contributor to the expansion of drug resistance [7].
Due to the appearance and prevalence of drug resistant malaria, many scientists
have devoted time to exploring new treatment plans to counter the disease. Com-
bination therapy has been used successfully, as it is unlikely that the parasite can
become resistant to two or more drugs at one time. However, combination therapy is
more expensive which can negate much of its effectiveness.
Although we are constrained by drug resistance, we are not defeated entirely in
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our efforts to cure diseases. Research is constantly being updated to account for
new developments in drugs and vaccines. In addition, educating the public about
the importance of the correct use of medicine can help reduce this development of
resistance from occurring as frequently.
2.6 Effects of Poverty
One of the major difficulties in the fight to overcome drug resistance is poverty. Poor
conditions make it difficult to correctly diagnose and treat the disease consistently.
To make matters worse, many of the people in desparate need of treatment simply
cannot afford it [8].
“It is estimated that a single bout of malaria costs a sum equivalent to over
10 working days in Africa. The cost of treatment is between $0.08 USD
and $5.30 USD according to the type of drugs prescribed as determined
by local drug resistance [8].”
Many researchers believe this cycle of illness continues to hinder the people’s
ability to advance. Poverty induces conditions that will cause them to obtain and
retain the disease.
“Beyond the human toll, malaria wreaks significant economic havoc in
high-rate areas, decreasing Gross Domestic Product (GDP) by as much
as 1.3% in countries with high levels of transmission. Over the long-term,
these aggregated annual losses have resulted in substantial differences in
GDP between countries with and without malaria (particularly in Africa).
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Malaria’s health costs include both personal and public expenditures on
prevention and treatment. In some heavy-burden countries, the disease
accounts for: up to 40% of public health expenditures, 30% to 50% of
inpatient hospital admissions, and up to 60% of outpatient health clinic
visits. Malaria disproportionately affects poor people who cannot afford
treatment or have limited access to health care, and traps families and
communities in a downward spiral of poverty [9].”
Illness causes individuals to lose valuable days of school or work, which only
restricts their ability to develop further. The lack of education also inhibits their
ability to fully understand the disease and the importance of using treatment only
when they are infected as well as for the correct amount of time. In the end, malaria
is one of the major culprits for children missing school and adults missing work which
translates to loss of education and lower wages.
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Chapter 3
Mathematical Models
3.1 Background
Mathematical models have been used for centuries to develop a better understanding
of systems in order to control or optimize results. A wide range of applications include
everything from radar development to production rates within factories to the spread
of disease. Mathematical models concerned with the spread of infectious diseases are
referred to as epidemic models. Models are created to study treatment and infection
rates in order to optimize our ability to predict, quarantine and control disease.
3.2 Kermack and McKendrick’s SIR Model
One of the first epidemic models, the SIR model, was a result of the work of O.
Kermack and Anderson Gray McKendrick [4]. The SIR model studied the movement
of populations between the susceptible class, the infected class, and the recovered
class, hence the name, SIR model. Kermack and McKendrick proposed a nonlinear,
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compartmental model with a constant total population, N [4]. Though relatively
simple, this model proved to be useful in providing a resource that allows one to
predict and hopefully mitigate the results of an epidemic.
Figure 3.1: Susceptible-Infected-Recovered Flowchart
To begin studying the movement between the classes, we will lay out a system
of differential equations that represent the status of infection. The rate of change
of susceptible people is proportional to the product of the number of people in the
susceptible and infected classes. This rate is negative since the number of people in
this class is decreasing.
κ is the constant of proportionality. In this case, κ represents the contact rate, or
the likelihood that a susceptible person would become infected through interaction
with an infectious person.
dS
dt
= −κIS (3.1)
The rate of change of the infected population grows at the same rate the suscep-
tible class decreases. The recovery rate, λ, is the likelihood that an infected person
would recover, with 1
λ
being the time it takes to recover.
dI
dt
= κIS − λI (3.2)
The recovered population is growing proportional to the product of the infected
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class and the recovery rate, λ.
dR
dt
= λI (3.3)
Equations 3.1, 3.2, and 3.3 are defined such that
dS
dt
+
dI
dt
+
dR
dt
= 0 (3.4)
and
S + I +R = N, (3.5)
where N represents the total population. This means that we are assuming the total
population is constant.
3.3 An SIR Model with Vital Dynamics
Many other variables and parameters can be considered when creating an epidemic
model. Other models that are in use today include variables that account for latency,
temporary immunity, drug resistance, multiple infections, and vaccination. The trade
off remains a balance between creating a more accurate model that affords the ability
to study details or a model that is easier to work with functionally omitting some of
the facts [4]. The following model accounts for vital dynamics, or changes within the
population size due to birth and death rates.
This model is a revised form of the previously mentioned SIR model to account for
birth, represented by β, as well as death, represented by µ [4]. We modify Equations
3.1, 3.2, and 3.3 to get the following system.
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dS
dt
= −κIS − µS + βN (3.6)
dI
dt
= κIS − λI − µI (3.7)
dR
dt
= λI − µR (3.8)
such that
µ = β (3.9)
to keep a constant total population.
The susceptible population grows in accordance with the birth rate, β, which is
proportional to the total population, N. The susceptible population decreases as a
result of infection, −κIS, or death, −µS.
The infected population grows in proportion to the product of the infected pop-
ulation, the susceptible population, and the contact rate, κIS. The infected class
decreases due to recovery, −λI, and death, −µI.
The recovered population grows in accordance with the recovery rate, which is
proportional to the size of the infected population, λI, and decreases due to the
death rate which is proportional to the recovered population, −µR.
3.4 Ross MacDonald Malaria Model
With a variety of books and published works including [11], [12], and [13]. Ronald
Ross was one of the first to conduct breakthrough research on malaria due to his
discovery that malaria is transmitted to human hosts via bites from mosquitoes. With
his first book published in 1902, Ross was a pioneer of malaria research. His studies
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afforded him countless honors and awards, including the Nobel Prize for Medicine.
Ross reported in his observations in Mauritius, an island off the coast of Africa,
that several elements contribute to the spread of malaria. Some elements include
details about the human population while others are concerned with the mosquito
population.
The Ross MacDonald Malaria Model is different from the previous models in
that it takes into account two different species and the interactions that take place
between them. Previous models were only concerned with tracking the population
changes within a single species. A clever simplification affords the ability to track
both the infectious and the susceptible populations of two species while only using two
equations. He assumes that a human or mosquito that is not infected is susceptible
to the disease.
The Ross MacDonald Malaria Model is comprised of two components: the propor-
tion of infectious humans, x, and the proportion of the female mosquito population
that is infected, y. These populations are affected by several parameters that include
the rate of infection passed to humans by the mosquitoes, α, the average duration of
a human infection, 1
r
, the average lifetime of a mosquito, 1
µ
, and the rate of infection
of mosquitoes by humans, β.
Let
dx
dt
= αy(1− x)− rx (3.10)
dy
dt
= βx(1− y)− µy (3.11)
where the total human and mosquito populations remain constant [4].
The infected class of humans increases due to the contact rate, α, which is pro-
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portional to the number of susceptible humans, 1 − x, and infected mosquitoes, y.
This growing population of infected humans is then reduced by the recovery rate, r,
proportional to the number of infected humans, x.
The infected class of mosquitoes increases due to the contact rate, β, which is
proportional to the number of infected humans and susceptible mosquitoes. The
infected mosquitoes are then reduced by the natural death rate, µy, proportional to
the number of infected mosquitoes, y.
This model was published initially by Ross in 1908 and further explorations and
refinements were mentioned subsequently through 1916. The model did not expe-
rience significant updates until 1952 when Dr. George MacDonald discovered some
interesting results as he studied the endemic equilibria of the model. MacDonald
also made advances in his studies of the reproductive number, a ratio that deter-
mines whether or not the epidemic will sustain or fail. Ross and MacDonald’s work
continue to be the foundation for epidemic models today.
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Chapter 4
A Model for Drug Resistant
Malaria
4.1 Drug Resistance
As drug resistance becomes increasingly common, it is necessary to study the effects
resistance has on treatment regimens. The World Health Organization defined three
levels of resistance to be:
• RI: recrudescence following parasite clearance (at least 2 consecutive days with
no detectable asexual parasites within 7 days after start of treatment)
• RII: no clearance and asexual parasitaemia below 25% of initial parasitemia 48
hours after start of treatment
• RIII: no clearance and asexual parasitaemia above 25% of initial parasitemia
48 hours after start of treatment [15]
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By addressing drug resistance within a mathematical model, we can identify patterns
of interest. Different scenarios can be studied by simulating what happens in the
real world and analyzing the results. We could study the effects of treatment by
changing the treatment rate or the effects of preventative measures by reducing the
contact rate. The results provide health care professionals the information they need
to make informed and more appropriate decisions. As we will see in the following
sections, drug resistance is tied very closely to the percentage of the population that is
treated. Therefore reducing the effects of malaria is not as simple as merely increasing
treatment.
4.2 Classifications
This model is partitioned into eleven classes that interact with each other. There
are two main categories of populations: the human population and the mosquito
population. The human population has eight classes that account for Sensitive: Sh,
Latent: Lh, Infected: Ih, Treated: Th, Withdrawn: Wh, and Resistant Classes RI: Rh1,
RII: Rh2, and RIII: Rh3. Individuals fall into the sensitive category when they have
never been infected with malaria, or when they have recovered completely without any
residual immunity from the prior infection. The latent class includes all humans that
have experienced a bite from an infected mosquito, prior to experiencing symptoms.
This stage will include humans that have the parasite multiplying in their liver, but
the parasites have not yet progressed into the red blood cells.
The infected class includes all humans that are experiencing symptoms of malaria
which are brought on by the replication of parasites within the red blood cells. The
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treated class includes all humans that have received treatment regardless of outcome.
An individual will progress to the withdrawn class when they experience temporary
immunity due to recovery from malaria. To enter the resistance classes, a human must
undergo treatment without successful results. The level of resistance is determined by
the reduction in asexual parasitemia, as discussed in Section 4.1. Movement within
the class structure of the human population can be studied via the flowchart depicted
in Figure 4.1.
Figure 4.1: Flowchart Detailing Movement Between the Human Population Classes
There are three classes used to identify the mosquito population. They include
the Sensitive, Latent, and Infected mosquitoes, with the definitions being similar to
those for the human population. Refer to Figure 4.2 for more details.
20
Figure 4.2: Flowchart Detailing Movement Between the Vector Population Classes
4.3 Model Formulation and Assumptions
Although malaria incidences rise and fall depending on factors such as rainfall and
temperature, we assume that malaria infections are uniformly transmitted throughout
the year for modeling purposes. An important component of this model is drug
resistance which is compartmentalized into three classes. Drug resistance develops as
a result of genetic mutations or it can be caused by natural selection due to low level
exposure to a drug that does not fully kill the parasite. Drug resistance may arise
due to an ineffective treatment regimen.
dSh(t)
dt
= Λh − fh(t)Sh(t) + ρWh(t)− dhSh(t),
dLh(t)
dt
= fh(t)Sh(t)− (ωh + dh)Lh(t),
dIh(t)
dt
= ωhLh(t)− (θ + ηI + dh + δh)Ih(t),
dTh(t)
dt
= θIh(t)− (ηT + λ1 + dh)Th(t),
dRh1(t)
dt
= λ1Th(t)− (η1 + λ2 + dh + a1δh)Rh1(t),
dRh2(t)
dt
= λ2Rh1(t)− (η2 + λ3 + dh + a2δh)Rh2(t),
dRh3(t)
dt
= λ3Rh2(t)− (η3 + dh + a3δh)Rh3(t),
dWh(t)
dt
= ηIIh(t) + ηTTh(t) + η1Rh1(t) + η2Rh2(t) + η3Rh3(t)
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−(ρ+ dh)Wh(t),
dSv(t)
dt
= Λv − fv(t)Sv(t)− dvSv(t),
dLv(t)
dt
= fv(t)Sv(t)− (ωv + dv)Lv(t),
dIv(t)
dt
= ωvLv(t)− (dv + δv)Iv(t),
with
fh(t) = βhc
Iv(t)
Nh(t)
(4.1)
and
fv(t) = βvc
Ih(t) + ηTTh(t) + η1Rh1(t) + η2Rh2(t) + η3Rh3(t)
Nh(t)
. (4.2)
Infection is passed from mosquitoes to humans in proportion to the contact rate,
βh, much like κ mentioned in Section 3.2. The magnitude of the contact rate,
βh, defined in fh is affected by several factors, including the proportion of infected
mosquitoes relative to the total human population, Iv(t)
Nh(t)
, as well as the size of the
susceptible human class, Sh.
Infection can also be passed from humans to mosquitoes via βv, contained in
the function fv. A mosquito can obtain infection by biting a human in any of the
infectious classes which include: Ih, Th, Rh1, Rh2, or Rh3. Thus the proportion of the
populations within these classes relative to the total human population is taken into
account, along with the size of the susceptible mosquito subpopulation, Sv.
The susceptible class grows in accordance with the birth rate, Λh, and the re-
covery rate proportional to the withdrawn subpopulation, ρWh(t). The susceptible
class decreases due to the contact rate proportional to the susceptible population,
−fh(t)Sh(t), or due to the natural death rate, −dhSh(t).
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The latent class will become larger by introducing humans that have been bitten
by an infected mosquito, fh(t)Sh(t). The latent class is reduced by the proportion of
people experiencing symptoms of malaria, −ωhLh(t), or by the death rate, −dhLh(t).
The infected class increases proportional to the decrease experienced within the
latent population, ωhLh(t). There are several decreasing rates of change within the
infected class: the treatment rate, −θIh(t), the recovery rate, −ηIh(t), the natural
death rate, −dhIh(t), and the infection-induced death rate, −δhIh(t), with all rates
used in proportion to the infected class.
The treated class is increasing due to the treatment rate proportional to the
infected population, θIh(t). Treated humans experience a decreasing rate of change
due to recovery, −ηTTh(t), the appearance of RI-level drug resistance, −λ1Th(t), or
due to the natural death rate, −dhTh(t). The outcome of treatment will determine
whether or not the infection is sensitive or resistant to drugs.
The RI class of humans experiencing the first level of drug resistance grows after
treatment failure, λ1Th(t). Humans can either recover, −η1Rh1(t), progress to RII
resistance class, −λ2Rh1(t), or they die,−(dh + a1δh)Rh1(t).
The RII class grows as people move from the RI resistance class, λ2Rh1(t). Humans
can then either recover, −η2Rh2(t), progress to RIII resistance class, −λ3Rh2(t), or
they die,−(dh + a2δh)Rh2(t).
Additions to RIII resistance class are a result of humans experiencing RII resis-
tance failing to recover or respond to treatment, λ3Rh2(t). At this stage, humans can
recover, −η3Rh3(t), or they die,−(dh + a3δh)Rh3(t).
The withdrawn population includes all humans that have recovered and are tem-
porarily immune regardless of which class they come from. Thus Wh is increasing due
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to the following rates of change: ηIIh(t) + ηTTh(t) + η1Rh1(t) + η2Rh2(t) + η3Rh3(t).
Humans leave the withdrawn class after losing immunity, and thus Wh also has a de-
creasing rate of change to account for losing immunity, −ρWh(t), or dying, −dhWh(t).
After a period of time, specifically 1
ρ
, an individual will lose temporary immunity to
re-enter the susceptible class. These individuals are fully susceptible to re-infection.
Similarly, the mosquito population is adjusted based on their infection status.
The susceptible mosquito population increases due to their birth rate, Λv. Suscepti-
ble mosquitoes are decreasing via the contact rate, βv contained in the function fv
or by the natural death rate, −dvSv(t), both of which are proportional to the sus-
ceptible mosquito class. The latent mosquito population experiences an increasing
rate of change proportional to the susceptible class, fv(t)Sv(t). Latent mosquitoes
can then either obtain the infection, −ωvLv(t), or die, −dvLv(t). While the infectious
mosquito class will become larger due to the rate at which latent mosquitoes obtain
infections, ωvLv(t), the infectious mosquitoes will eventually die without recovering
from infection, −(dv + δv)Iv(t).
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Chapter 5
Results
5.1 Parameters
In this section, we examine the effects of treatment rates and drug resistance rates
on the subpopulation sizes. Many of the parameter values used are based on values
found in [6]. See Table 5.1. In this study, they found two sets of parameter values
based on high and low transmission areas depending on the force of infection and
contact rates between humans and mosquitoes. The parameters were derived using
data from various sources such as the Central Intelligence Agency, field studies, and
long term data collection through observation. We chose parameter values from their
model that functioned similarly to our parameters.
We made a few assumptions with regard to the parameters in [6]. The death rate
was split into two parameter values accounting for a density independent death rate
as well as a density dependent death rate that was multiplied by the total population.
For our model, we chose to use only the density independent death rate.
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Table 5.1: Parameter Values
Parameter Dimension Value
Λh Humans × Day−1 5.533
ρ Day−1 0.00055
dh Day
−1 0.000016
ωh Day
−1 0.1
δh Day
−1 9.0× 10−5
βh Day
−1 0.022
Λv Mosquitoes × Day−1 39000
dv Day
−1 0.033
ωv Day
−1 0.091
βv Day
−1 0.48
δv Day
−1 0.0165
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Another modification was made regarding Λh. In [6], they accounted for birth
as well as immigration, with the birth rate depending upon the size of the total
population. In order to account for both values, we combined them by adding their
immigration rate with the product of the birth rate and the initial population. We
made similar modifications when using the parameter values for mosquitoes.
Some parameter values were not available in [6]. These include ηT , ηI , η1, η2, η3,
a1, a2, a3, and c, which can enhance the contact rate as well as the malaria induced
death rate. The ηi values were estimated to be 0.05. We approximated the time
an individual spends in the infected or resistance classes to be about three weeks.
Similarly, the time spent to treat an infection could last about a week. So, ηT is
1
0.14
≈ 7 days.
a1, a2, a3 enhance the malaria induced death rate experienced at each resistance
level. It is feasible that the death rate could be higher if an infection is not sensitive
to treatment, but for simplification, our simulations set these values equal to one.
The parameter c incorporates the bite rate, which can enhance the transmission of
infections between humans and mosquitoes. Although slight changes to c can create
large differences in the results, this parameter is set equal to one for simplification.
However, studying the effects of c could provide insight into prevention programs
mentioned such as mosquito control by simulating the reduction in the bite rate due
to ITNs.
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5.2 Numerical Results
We conducted numerical simulations using a simple forward Euler scheme and varied
both the percentage of people that were treated as well as the resistance rates. We
assumed a human population size of 50,000 and a mosquito population size of 390,000.
Also, we assumed that initially there was no treatment occurring with approximately
6% of the population being latent and approximately 24% of the population being
infected. Table 5.2 has the number of people (rounded normally) in Th, Rh1, Rh2, and
Rh3. The values shown represent the number of people that had the parasite in their
system after 1,000 days since the treatment started, which is about 3 years. These
values are near the steady state values of the system.
Resistance rates vary from place to place. One of the “hot spots” for resistance is
near the Thailand-Myanmar border, where they see rates of resistance from 4.5% to
21.9% [5]. Since we are interested in drug resistance, we decided to vary parameters
that would affect the level of resistance experienced by the human population. For
the remainder of the discussion, we refer to low resistance as 4.5%, medium resistance
as 13.2%, and high resistance as 21.9%, where this percentage controls the likelihood
that a person would become resistant.
We partition our exploration of treatment and resistance into two categories. First,
we focus on how increasing the percentage of people that receive treatment affects the
number of people in each class. We will also speak of the changes to the infectious
group as a whole, which is the sum of Ih, Th, Rh1, Rh2, and Rh3. Then, we investigate
the effects of drug resistance by comparing low, medium, and high levels of resistance.
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5.2.1 Varying the Treatment Rate at Each Level of Resis-
tance
As we survey the results, we discover that the old adage “less is more” holds true
with respect to treatment rates. We will walk through each subpopulation speaking
of the change that is experienced as we double the treatment rate starting with a 10%
level. The biggest decrease in the infectious subpopulation is seen when comparing
10% to 20% treatment rates. By the time 80% is attained, the results are much less
significant. Thus, increasing treatment alone is not a valid solution. It is clear that
our approach must be more sophisticated than merely providing antimalarial drugs
to endemic regions. Refer to Table 5.2 for details.
The latent class experiences almost no change during these manipulations. The
steadiness of the latent group makes sense due to the fact that the parameters affecting
the entrance or exit from the latent class were not changed.
The infected class, however, does change. As treatment increases from 10% to 20%
the infected group drops 40%. Doubling treatment from 20% to 40% treatment rate
provides a decrease of 44%. Comparing the 40% to 80% treatment rate, the decrease
in the infected class is 47%. This large and consistent reduction is to be expected,
since the goal of administering treatment is to shrink the infected subpopulation.
The treated class grows steadily as we increase treatment. The treated class
increases 20% as we double the treatment rate from 10% to 20%. As we double the
treatment rate again to achieve 40% treatment, we witness only an 11% increase in
the treated class. Doubling treatment a final time to attain 80% treatment yields an
even smaller increase in the treated group at 6%. Thus, treating 20% as opposed to
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Table 5.2: Long Term Population Values - High Transmission Case
θ λh1, λh2, λh3 Lh Ih Th Rh1 Rh2 Rh3
10% 4.5% 341 227 123 58 27 25
20% 4.5% 341 136 147 70 33 30
40% 4.5% 340 76 163 77 37 33
80% 4.5% 340 40 173 82 39 35
10% 13.2% 342 228 84 61 44 116
20% 13.2% 342 137 100 73 53 139
40% 13.2% 341 76 112 81 59 154
80% 13.2% 341 40 118 86 62 163
10% 21.9% 342 228 63 52 42 183
20% 21.9% 342 137 76 62 50 220
40% 21.9% 342 76 85 69 56 244
80% 21.9% 342 40 90 73 59 259
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10% yields a formidable change while doubling the treatment rate thereafter produces
increasingly smaller changes. It is important to note that managing a treatment rate
of 40% or more would be expensive as well as difficult. Thus, the most “bang for
your buck” may be achieved at a lower level of treatment.
Rh1 follows a similar pattern to the one noted for the treated class as it increases
steadily as treatment is increased. Beginning with a 10% treatment rate and doubling
treatment produces a 20% increase in Rh1. Doubling treatment again to obtain 40%
treatment, we see a 10% increase. Doubling the treatment once more to 80% gives
us a 6% increase in the subpopulation size.
Rh2 follows a similar pattern of increasing size. Comparing the 10% treatment
rate to the 20% treatment rate, we witness a 22% increase. As we move from 20%
to 40% treatment, there is an additional 12% increase. Increasing treatment to 80%
yields an extra 5% of people in the Rh2 class.
Rh3 has the same percentage of increase as Rh1. Moving from 20% to 10% to 6%
growth as we double the treatment rate moving from 10% to 80% treatment rates.
The contact rate βv is affected by the magnitude of all infectious people which
include Ih, Th, Rh1, Rh2, and Rh3. As we double the treatment rate from 10% to
20%, the sum of all infectious people decreases 10% in a low resistance case. This
response to treatment, however, diminishes at the higher levels of resistance. When
treatment is increased from 10% to 20% at the high resistance level, the change within
the infectious group is only 4%; less than half of the change seen at the low resistance
level.
31
5.2.2 Varying the Level of Resistance at Each Treatment
Rate
Table 5.3: Long Term Population Percentage of Change due to Resistance
Change in Resistance Th Rh1 Rh2 Rh3 All Infectious
10% Treatment
Low to Med -32% 5% 63% 364% 16%
Med to High -25% -15% -5% 58% 7%
20% Treatment
Low to Med -32% 4% 61% 363% 21%
Med to High -24% -15% -6% 58% 9%
40% Treatment
Low to Med -31% 5% 59% 367% 25%
Med to High -24% -15% -5% 58% 10%
80% Treatment
Low to Med -32% 5% 59% 366% 27%
Med to High -24% -15% -5% 59% 11%
Now we will alter the resistance rates to examine the effects on the population. To
simplify, we will refer to changes within the resistance levels at a 10% treatment rate
unless otherwise stated. It should be noted that the percentage of change is similar
within each treatment group.
As we will see in the following section, varying the resistance rates produces a
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much larger increase in the infectious group when studying the 80% treatment rate
versus the 10% treatment rate. This result tells us that we are much more likely
to experience a higher level of drug resistance when treatment is easily accessible to
a large proportion of the population. The greatest change can be seen in the Rh3
class, with an explosive increase in size as we compare the low and medium levels of
resistance.
Th decreases from 123 people to 84 people moving from low to medium resistance,
a change of 32%. While, moving from medium to high resistance produces a 25%
decrease in the treated class. Due to the fact that we are increasing resistance to
treatment, we would expect more people to end up in a resistance class instead of the
treated class.
As we increase the resistance from low to medium, Rh1 increases 5%. As we
increase resistance from medium to high, however, Rh1 decreases 15%. So, changing
from low to medium resistance causes Rh1 to increase in size slightly, while moving
from medium to high resistance causes a considerable 15% drop in the size of Rh1.
Rh2 behaves similarly, with a more dramatic increase at 63% followed by a smaller
5% decrease.
Rh3 behaves in an opposite fashion. Instead of increasing and decreasing, Rh3
more than triples its size and then only continues to increase. Rh3 experiences a
364% increase from low to medium resistance and an additional 58% increase as we
progress to high resistance.
Consider the effects of resistance on the infectious group: Ih, Th, Rh1, Rh2, and
Rh3. We see a 16% increase in the infectious class as we compare the low and medium
levels of resistance. The increase as we move from medium to high levels of resistance
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is 7%. It is worth noting that the infectious subpopulation still increases even if at a
lesser rate.
5.2.3 Increasing and Decreasing Resistance Rates
All of the results that have been discussed assume that the resistance rates, λ1, λ2,
and λ3 are equal. We will now examine how using different resistance rates affects
the population. When we refer to Increasing Resistance we mean that λ1 = 4.5%,
λ2 = 13.2%, and λ3 = 21.9%. In this case, we are simulating the possibility that it is
less likely that you will obtain resistance in the first place, but if you do become RI
resistant, then you are more likely to progress to RII and even more likely to become
RIII resistant.
In the increasing resistance case, the latent, infected, and treated classes behave
in much the same way as the constant resistance rates. We will therefore focus our
attention to the changes within the resistance classes.
Rh1 increases from 30 to 36 people as we increase treatment from 10% to 20%.
This results in a 20% increase. As we progress to 40%, we see an additional 11%
increase to a total of 40 people. Doubling treatment a final time yields 43 people for
a 6% change.
Rh2 and Rh3 follow a similar progression as their percentage of change as we
increase treatment goes from 20% to 11% and finally 6%. This behavior is much like
the changes observed when using constant resistance.
When we refer to Decreasing Resistance, we are examining the opposite scenario.
Thus, we will assume that it is easier to obtain RI resistance than RII resistance
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Table 5.4: Long Term Population Values - Increasing and Decreasing Resistance Rates
θ Lh Ih Th Rh1 Rh2 Rh3
Increasing
10% 341 227 123 30 15 65
20% 341 136 147 36 18 78
40% 340 76 163 40 20 86
80% 340 40 173 43 21 91
Decreasing
10% 342 228 63 76 106 95
20% 342 137 76 92 127 114
40% 342 76 85 102 141 126
80% 342 40 90 108 149 134
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and even less likely that you will become RIII resistant. We achieve this by setting
λ1 = 21.9%, λ2 = 13.2%, and λ3 = 4.5%.
Behavior for Lh, Ih, and Th is the same as in the constant resistance rates. Rh1,
Rh2, and Rh3 experience the same percentage of change as the constant resistance
rates, but the actual number of people in each is slightly different. Thus, all of the
resistance classes increase 20%, 11%, and then 6% as we increase treatment. This
percentage of change is identical to both the constant resistance rates as well as the
increasing resistance case.
5.3 Areas of Low Transmission
Simulations for areas of low transmission were also analyzed by adjusting the resis-
tance levels and the treatment rate. The baseline values for the low transmission
parameters are shown in Table 5.5.
When comparing the high transmission case with the low transmission case, an
interesting result appears. The progression through the treatment rates and the resis-
tance levels yield near identical percentages of change. However, the subpopulation
sizes for the low transmission case within Lh, Ih, Th, Rh1, Rh2, and Rh3 are signifi-
cantly larger than those subpopulations in the high transmission case. For instance,
the infected class at a 10% treatment rate in the high transmission case is 227 people.
The same value in the low transmission case is 853 people, an increase of 276%. Every
instance of comparing like numbers moving from areas of high transmission to low
transmission yields a similar increase that ranges between 271% and 283%.
Comparing areas of high and low transmission, the parameters that were adjusted
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Table 5.5: Parameter Values
Parameter Dimension Value
Λh Humans × Day−1 2.791
ρ Day−1 0.0027
dh Day
−1 0.0000088
ωh Day
−1 0.1
δh Day
−1 1.8× 10−5
βh Day
−1 0.022
Λv Mosquitoes × Day−1 39000
dv Day
−1 0.033
ωv Day
−1 0.083
βv Day
−1 0.24
δv Day
−1 0.0165
include the recovery rate: ρ, the human birth rate: Λh, the human death rate: dh,
the malaria-induced death rate for humans: δh, the bite rate for mosquitoes: βv, and
the infection rate for mosquitoes: ωv. In the low transmission case, the amount of
people recovering, ρ, increased 80%. The human birth rate, Λh, was reduced 98% for
the low transmission case. The human death rate, dh, was reduced by 82%, while δh
is reduced by 400%. The mosquito population was affected by the 100% reduction in
the bite rate, βv, as well as the 10% reduction in the infection rate, ωv.
Although the human birth rate decreased, the human death rates are even smaller
in comparison which accounts for some of the difference between high and low trans-
mission. The major change, however, is the recovery rate with is more than tripled.
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This increased recovery rate allows people to move back into the susceptible class
much faster, thereby obtaining new infections. In the high transmission case, once a
person is withdrawn, they sustain temporary immunity for nearly five years. How-
ever, in the low transmission case, temporary immunity lasts just over a year. This
single change almost doubles the amount of people within the susceptible class which
allows a greater proportion of people to become infected. βv is also reduced, but
notice that this parameter is then multiplied by the proportion of infectious people
which has been increased a significant amount.
Table 5.6: Long Term Population Values - Low Transmission Case
θ λh1, λh2, λh3 Lh Ih Th Rh1 Rh2 Rh3
10% 4.5% 1280 853 461 218 103 93
20% 4.5% 1279 511 553 262 124 111
40% 4.5% 1276 284 613 290 137 123
80% 4.5% 1275 150 648 307 145 131
10% 13.2% 1281 854 314 228 165 435
20% 13.2% 1281 512 377 273 198 522
40% 13.2% 1281 285 418 303 220 580
80% 13.2% 1281 151 443 321 233 614
10% 21.9% 1281 854 238 194 158 689
20% 21.9% 1281 512 285 232 189 827
40% 21.9% 1281 285 317 258 210 919
80% 21.9% 1281 151 336 273 222 973
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5.4 Conclusions
As we have seen, the infectious population is responsive to both changes in treatment
as well as changes in the levels of drug resistance that are experienced. Increasing
the percentage of people receiving treatment causes the infectious population to drop.
However, this decrease in the infectious group becomes much less significant as we
move from low to high levels of resistance. In other words, treatment can be effective
in reducing the number of people that are sick if the drug resistance is not too high.
On the other hand, once drug resistance becomes prevalent, treatment is less likely to
be successful. As we study the high resistance case, we see that increasing treatment
leads to a major increase in the drug resistant population with minimal reduction in
the infectious group as a whole. In this case, mathematical models such as this one
can help suggest thresholds in which treatment would be effective and when treatment
should be used conservatively to avoid creating more problems by aggravating drug
resistance.
A cost-benefit analysis of treatment rates can be analyzed using mathematical
simulations. In our study, we discovered that increasing treatment yields a smaller
decrease of infectious individuals. In other words, doubling the treatment rate may
produce significant changes in the size of the infectious subpopulation, but this ef-
fectiveness decays as we continue to increase treatment. A balance can be found
such that treating a certain percentage of people would yield optimal effectiveness
per dollar spent.
Varying constant levels of resistance provided insight by the differences of growth
in the resistance classes, Rh1, Rh2, and Rh3. Moving from low to medium resistance,
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Rh1 increases slightly. Increasing from medium to high resistance, Rh1 actually be-
comes smaller. Similarly for Rh2, the same progression from low to medium to high
resistance induces an increase in Rh2 followed by a decrease. Rh3, however, grows
dramatically from low to medium resistance with another increase as we progress
from medium to high. Thus, more individuals will acquire RIII resistance as resis-
tance to treatment becomes more prevalent. Several components are at work in this
case. As we increase resistance by increasing λi, we are not only allowing more peo-
ple to move in to the resistance classes, but we are also moving them through the
resistance classes at a faster pace since 1
λi
is the time a person is in the resistance
class. Throughout our parameter manipulations, we do not change the recovery rate
and thus the proportion of people recovering becomes fewer in comparison to those
obtaining drug resistant malaria.
As a result of our research, we are painfully aware of the implications that treat-
ment has on drug resistance. All of our simulations have reinforced the strong cause
and effect relationship that exists between resistance and treatment. Innately, we
desire to aid those that suffer by administering antimalarial drugs, but as a result
we are reducing the effectiveness of the drugs. Although treatment cures some cases
of malaria, the cost of an influx of drug resistant strains of the parasite must be
considered.
From the simulations that were conducted, we continue to gain confidence that
our model acts similarly to real world scenarios. Using our knowledge of malaria
and drug resistance, further studies can refine the selections that were made for the
parameter values and the initial conditions. Many more areas of the model can and
should be explored to better understand the implications of treatment and how it
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affects drug resistance. Ongoing research and analysis will hopefully help the world
get closer to eliminating the burden of infectious diseases. The trade off, however,
must be made between treating symptoms and creating a more volatile and resistant
disease. Care must be taken when evaluating treatment plans, which is one of the
most useful ways to leverage mathematical models.
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Appendix A
Parameter Descriptions and Initial
Conditions
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Table A.1: Human Parameter Descriptions
Parameter Description
Λh Rate at which new recruits enter the susceptible human population
βv Rate at which a human receives a successful bite from an infected mosquito
c A constant that will increase or decrease the frequency of bites
ρ Rate at which humans lose partial immunity
dh Natural death rate for humans
δh Malaria-induced death rate for humans
ωh Rate that humans become infectious after they have been exposed
θh Treatment rate for humans
ηI Rate that humans acquire partial immunity prior to treatment
ηT Rate that treated humans acquire partial immunity
η1 Rate that humans in the first resistance class acquire partial immunity
η2 Rate that humans in the second resistance class acquire partial immunity
η3 Rate that humans in the third resistance class acquire partial immunity
λ1 Rate that humans become RI resistant after receiving treatment
λ2 Rate that humans become RII resistant after receiving treatment
λ3 Rate that humans become RIII resistant after receiving treatment
a1 Rate that the malaria-induced death rate increases due to RI resistance
a2 Rate that the malaria-induced death rate increases due to RII resistance
a3 Rate that the malaria-induced death rate increases due to RIII resistance
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Table A.2: Vector Parameter Descriptions
Parameter Description
Λv Rate at which new recruits enter the susceptible mosquito population
βh Rate at which a susceptible mosquito successfully bites an infected human
δv Malaria-induced death rate for mosquitoes
dv Natural death rate for mosquitoes
Ωv Rate that mosquitoes become infectious after they have been exposed
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Table A.3: Initial Conditions - High Transmission
Parameter Value
Λh 5.533
βv 0.48
ρ 0.00055
dh 0.000016
δh 0.00009
ωh 0.1
ηI 0.05
ηT 0.14
η1 0.05
η2 0.05
η3 0.05
Λv 39000
βh 0.022
δv 0.0165
dv 0.033
Ωv 0.091
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Table A.4: Initial Conditions - Low Transmission
Parameter Value
Λh 2.791
βv 0.24
ρ 0.0027
dh 0.0000088
δh 0.000018
ωh 0.1
ηI 0.05
ηT 0.14
η1 0.05
η2 0.05
η3 0.05
Λv 39000
βh 0.022
δv 0.0165
dv 0.033
Ωv 0.083
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Appendix B
Graphical Results
Results previously discussed focus on population sizes after an outbreak, once the
changes in population sizes become less drastic. The following graphs depict how an
outbreak of malaria would affect the population within the various classes, assuming
an area of high transmission.
B.1 High Resistance
Comparing Figures B.1 and B.2, it is clear that increasing treatment increases the
population in Rh3 by comparing the peak of the blue curve. A result that was men-
tioned when studying the populations after they settle.
B.2 Medium Resistance
Although the treatment rate affects the height of the peak in population size, qualita-
tively the results are the same. Th and Rh3 have approximately the same population
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Figure B.1: Th, Rh1, Rh2, and Rh2 Classes with High Resistance Levels and a 10%
Treatment Rate
Figure B.2: Th, Rh1, Rh2, and Rh2 Classes with High Resistance Levels and a 80%
Treatment Rate
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size, with the peak in Th arriving prior to Rh3. See Figure B.3.
Figure B.3: Th, Rh1, Rh2, and Rh2 Classes with Medium Resistance Levels and a
20% Treatment Rate
B.3 Low Resistance
We will continue examining outbreaks as they occur in the low resistance case. Figures
B.4 and B.5 show the difference between 20% and 40% treatment rates within the
low resistance case. Moving from 20% to 40% treatment rates, demonstrates a large
difference in the Rh3 class. In the 20% treatment case, the population that has the
largest peak is Th, but when we double treatment Rh3 becomes the population with
the largest increase. This illustrates an example where keeping treatment rates lower
may actually help the population overcome malaria with less resistance.
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Figure B.4: Th, Rh1, Rh2, and Rh2 Classes with Low Resistance Levels and a 20%
Treatment Rate
Figure B.5: Th, Rh1, Rh2, and Rh2 Classes with Low Resistance Levels and a 40%
Treatment Rate
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B.4 The Mosquito Population
Figure B.6 shows the change in the mosquito population as an outbreak occurs as-
suming a 10% treatment rate with low resistance. Notice the proportion of infected
and latent mosquitoes compared to the number of susceptible mosquitoes.
Figure B.6: The Mosquito Population with Low Resistance Levels and a 10% Treat-
ment Rate
51
Bibliography
[1] S.J. Aneke, Mathematical modelling of drug resistant malaria parasites and vec-
tor populations, Math. Meth. Appl. Sci. 25, 235-436 (2002).
[2] Bailey, Norman. The Biomathematics of Malaria, London: Charles Griffin &
Company Limited, 1982.
[3] P. Bloland, Drug resistance in Malaria, World Health Organization, Geneva:
WHO, 2001.
[4] Capasso, Vincenzo. Mathematical Structures of Epidemic Systems, New York:
Spinger-Verlag, 1993.
[5] V.I. Carrara, J. Zwang, E.A. Ashley, R.N. Price, K. Stepniewska, et al. Changes
in the treatment responses to Artesunate-Mequine on the Northwestern border
of Thailand during 13 years of continuous deployment. PLoS ONE 4(2): e4551.
doi:10.1371/journal.pone.0004551.
[6] N. Chitnis, J. Hyman, and J. Cushing. Determining Important Parameters in the
Spread of Malaria Through the Sensitivity Analysis of a Mathematical Model,
Bulletin of Mathematical Biology. 70, 1272-1296 (2008).
52
[7] Drug Resistance, Magill’s Medical Guide, Vol. 1, 661-665, Pasadena: Salem Press
Inc, 2002.
[8] Malaria. 1 Jan 2009. MicrobiologyBytes. 11 April 2009
http://www.microbiologybytes.com/introduction/Malaria.html
[9] Malaria: Economic Impact. 1 Jan 2009. World Health Organization. 7 Mar 2009
http://www.who.int/mediacentre/factsheets/fs094/en/index.html
[10] Malaria: A Global Burden. 1 Jan 2007. Malaria Control International. 1 Mar
2009 http://www.malariacontrolinternational.org/malaria.html.
[11] Ross, Ronald. Mosquito Brigades and How to Organize Them, London: George
Philip and Son, 1902.
[12] Ross, Ronald. The Prevention of Malaria, New York: E.P. Dutton and Company,
1910.
[13] Ross, Ronald. Report on the Prevention of Malaria in Mauritius, London: Wa-
terlow and Sons Limited, 1908.
[14] Susceptibility of Plasmodium Falciparum to Antimalarial Drugs. 1 Jan 2009.
World Health Organization. 11 Apr 2009. http://www.who.int/malaria/rbm/-
Attachment/20041108/SusceptibilityPlasmodium report.pdf
[15] WHO 1973 Chemotherapy of Malaria and Resistance to Antimalarials. Geneva.
World Health Organization, Technical report Series No 529.
[16] World Malaria Report. 1 Jan 2008. World Health Organization. 23 Mar 2009
http://malaria.who.int/wmr2008/malaria2008.pdf.
53
